ISPOR CLINICAL OUTCOME ASSESSMENT SPECIAL INTEREST GROUP - NEW FRONTIERS- VALUING COA DATA AND GUIDING PRINCIPLES FOR RWE
Author(s)
Moderator: Katja Rudell, PhD, MSc, Parexel Access Consulting, Parexel International, London, UK
Speakers: Lynda Doward, Master of Research, Patient Centered Outcomes Assessment, R T I Health Solutions, Manchester, UK; Bryan Bennett, PhD, Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, BKM, UK; Angela Jane Rylands, PhD, CPsychol, BSc, pH Associates (an OPEN Health company), Marlow, UK; Ana Maria Rodriguez, PhD MSc BScPT BSc, RWE Patient-Centered Endpoints CoE, IQVIA, Madrid, Spain
Presentation Documents
The two initiatives of the group include: a key project focusing on the value of COA data to external stakeholders, and a membership engagement project investigating approaches to standardizing COA for real world (RW) studies. The key project aims to update the terminology used by COA specialists and to publish this in the updated ISPOR book of terms. The work will involve the review of HTA terminology used for COA from different countries and to harmonize the way HEOR scientists and COA specialists describe COA value. The COA SIG membership engagement project will explore the standardization of COA in RW studies. A virtual roundtable meeting will be conducted with industry colleagues to discuss topics, such as the operationalization and scientific integration of COA in in the RW.
We will discuss the available results and the next phases of our two initiatives during this forum.